Info on all the Phr
From company website. ------------------- We are excited to work with Pfizer, Merck KGaA, Merck, Bristol-Myers Squibb, Roche, and Incyte with their checkpoint inhibitors, and look forward to developing our programs to evaluate the efficacy and safety in our clinical studies targeting metastatic breast cancer, early stage breast cancer, multiple myeloma and gastrointestinal cancer, including pancreatic, colorectal, and anal. There is great potential to eventually work with additional immunotherapies in additional indications and this will only drive the potential for treatment with pelareorep.